The Journal of Urology
Volume 178, Issue 6 , Pages 2277-2283 , December 2007

Conflicting and New Risk Factors for Contrast Induced Nephropathy

  • Omer Toprak

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Nephrology, Ataturk Training and Research Hospital, 35360 Izmir, Turkey (telephone: +90-232-244-4444/2690; FAX: +90-232-243-4848).

Received 15 December 2006

References 

  1. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113:1799
  2. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006;67:335
  3. Morcos SK, Thomsen HS European Society of Urogenital Radiology. European Society of Urogenital Radiology guidelines on administering contrast media. Abdom Imaging. 2003;28:187
  4. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older (A prospective study). Arch Intern Med. 1990;150:1237
  5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259
  6. Toprak O, Cirit M. Risk factors for contrast-induced nephropathy. Kidney Blood Press Res. 2006;29:84
  7. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology. 1992;183:519
  8. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68:14
  9. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393
  10. Caldicott WJ, Hollenberg NK, Abrams HL. Characteristics of response of renal vascular bed to contrast media (Evidence for vasoconstriction induced by renin-angiotensin system). Invest Radiol. 1970;5:539
  11. Workman RJ, Shaff MI, Jackson RV, Diggs J, Frazer MG, Briscoe C. Relationship of renal hemodynamic and functional changes following intravascular contrast to the renin-angiotensin system and renal prostacyclin in the dog. Invest Radiol. 1983;18:160
  12. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for preventing of contrast-induced nephropathy in diabetic patients: a randomized study. Indian Heart J. 1999;51:521
  13. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13
  14. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL. The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg. 2003;3:98
  15. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract. 2006;104:c20
  16. Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22:819
  17. Xiong XL, Jia RH, Yang DP, Ding GH. Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis. Pharmacol Res. 2006;54:253
  18. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both (A prospective controlled study). N Engl J Med. 1989;320:143
  19. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300
  20. Lautin EM, Freeman NJ, Schoenfeld AH, Bakal CW, Haramati N, Friedman AC, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol. 1991;157:49
  21. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv. 2003;59:338
  22. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491
  23. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72:701
  24. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692
  25. Baker CS, Wragg A, Kuna S, DePalma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-inducted renal dysfunction: the RAPPID Study. J Am Coll Cardiol. 2003;41:2114
  26. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284
  27. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41:815
  28. Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int. 2006;70:1811
  29. Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int. 1985;27:46
  30. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329
  31. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol. 2003;15:18
  32. Mueller C, Buerkle G, Perruchoud AP, Buettner HJ. Female sex and risk of contrast nephropathy after percutaneous coronary intervention. Can J Cardiol. 2004;20:505
  33. Swartz RD, Rubin JE, Leeming BW, Silva P. Renal failure following major angiography. Am J Med. 1978;65:31
  34. Najjar M, Hamad A, Salameh M, Agarwal A, Feinfeld DA. The risk of radiocontrast nephropathy in patients with cirrhosis. Ren Fail. 2002;24:11
  35. Guevara M, Fernandez-Esparrach G, Alessandria C, Torre A, Terra C, Montana X, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646
  36. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol. 2000;54:11
  37. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR Am J Roentgenol. 2006;186:1651
  38. Deray G, Mouquet C, Ourhama S, Bellin MF, Jacquiaud C, Luciani J, et al. Effects on renal haemodynamics and tubular function of the contrast medium Ioxaglate in renal transplant patients. Clin Radiol. 1995;50:476
  39. Vigneau C, Fulgencio JP, Godier A, Chalem Y, ElMetaoua S, Rondeau E, et al. The use of contrast media in deceased kidney donors does not affect initial graft function or graft survival. Kidney Int. 2006;70:1149
  40. Hietala SO, Segerstedt B, Wirell S, Sunnegardh O, Ostberg P, Osth L. Effects of contrast media on renal graft function and survival after cerebral angiography of cadaveric donors. Acta Radiol. 1989;30:317
  41. Toprak O, Cirit M, Yesil M, Byrne DW, Postaci N, Bayata S, et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res. 2006;29:2
  42. Andrade L, Campos SB, Seguro AC. Hypercholesterolemia aggravates radiocontrast nephrotoxicity: protective role of arginine. Kidney Int. 1998;53:1736
  43. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843
  44. Babu A, Fogelfeld L. Metabolic syndrome and prediabetes. Dis Mon. 2006;52:55
  45. Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents (A study in man of four commonly used preparations). Ann Intern Med. 1971;74:845
  46. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006;67:227
  47. Toprak O, Cirit M, Bayata S, Yesil M. Review of the radiocontrast nephropathy risk profiles and risk stratification. Anadolu Kardiyol Derg. 2004;4:331
  48. Kaur JS, Goldberg JP, Schrier RW. Acute renal failure following arteriography in a patient with polyarteritis nodosa. JAMA. 1982;247:833
  49. Vassiliu P, Sava J, Toutouzas KG, Velmahos GC. Is contrast as bad as we think? (Renal function after angiographic embolization of injured patients). J Am Coll Surg. 2002;194:142
  50. Marenzi G, Lauri G, Assanelli E, Campodonico J, DeMetrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780

PII: S0022-5347(07)02061-7

doi: 10.1016/j.juro.2007.08.054

The Journal of Urology
Volume 178, Issue 6 , Pages 2277-2283 , December 2007

Article Tools